Study suggests a way to eliminate glioblastoma

	Tweet

Scientists have devised a strategy to treat tumors by selectively targeting and killing the malignant cells. A new preclinical study, published in the open access journal PLoS Medicine, has applied the approach to combat glioblastoma multiforme (GBM).

This is the most aggressive form of brain tumour, growing very quickly before symptoms are experienced and killing most patients within a year of diagnosis.

Working in mice, Alexander Levitzki and colleagues (of The Hebrew University of Jerusalem and Ludwig-Maximilians-University in Munich) took advantage of previous research that showed how to distinguish between cancerous and healthy cells through the detection of molecules known as epidermal growth factor receptors (EGFR). The glioblastoma cells overexpress EGFR (that is, in comparison with normal brain cells, they have many more of these molecules on their surface). The scientists then selected a type of genetic material (a nucleic acid) associated with viral infections and linked it to a compound that could bind to EGFR. As a result of the defence mechanisms that have evolved to protect mammalian cells from viruses, cells are programmed to die once they take up this particular nucleic acid. The treatment therefore eliminates the tumor cells but avoids damage to the normal brain tissue.

The researchers found that the treatment was effective in mice implanted with human brain tumor cells that overexpressed EGFR. The treatment could eliminate established cancers and there was no evidence of recurrence: the mice remained cancer free for over a year.

It is more difficult to cure cancer in humans than cancer in mice, but the results are encouraging. In his Perspective article accompanying the study, Robert Weil of the Brain Tumor Institute at the Cleveland Clinic Foundation suggests that the approach deserves to be “fast-tracked to the clinic” given the lack of effective treatments for GBM. There are few existing options aside from chemotherapy and surgery to remove the tumor, and it is rare that these treatments stop the cancer from recurring.

Given the prevalence of EGFR in cells of other cancer types (such as breast cancer and lung cancer), the approach pioneered in this study may be applicable to other forms of cancer as well.

RELATED STORIES:
$1 million of mesothelioma research funding   Study reveals differences in cancer stage presentation between rural and urban patients   Study Predicts Dramatic Growth in Cancer Rates Among U.S. Elderly, Minorities   Childhood Leukemia Survivors Struggle With Long-Term Comorbidities   Children’s Cancer Group Recommends Global Evaluation System for Neuroblastoma to Improve Treatment   American men with cancer more likely to die than women   Small Gift Makes Big Impact in Lives of Cancer Patients   Mayo Clinic Researchers Find That Protein Believed to Protect Against Cancer Has a Mr. Hyde Side   Computer-aided mammography improves tumor detection   US cancer death rates decline, report finds   Simple test could cut cancer deaths in poor nations   Fugitive Cancer Cells Can be Blocked by Stopping Blood Cells That Aid Them   Factors that enhance autonomy of cancer patients   Genome study shows what cancers have in common   Cell Path Overdrive Prevents Cancer Response to Diet Restriction   Anti-Cancer Agent Stops Metastasis in Its Tracks   American Cancer Society report details cancer prevention efforts   Imaging Technology May Relieve Cancer Pain   Using magenetic nanoparticles to combat cancer   Nanocenter Offers Promising Non-Invasive Cancer Treatment   Cancer patients want honesty, compassion from their oncologist   Breastfeeding – added protection for cancer survivors?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]